Benzinga | Jul 13, 2020 05:32AM EDT

Amgen Announces $421M Investment In BeiGene

Amgen (NASDAQ:AMGN)today announced an additional investment of approximately $421 million in BeiGene's (NASDAQ:BGNE) registered direct offering of ordinary shares, which maintains Amgen's current pro rata ownership of BeiGene at approximately 20.3%. This additional investment reflects Amgen's confidence in the progress the companies are making in their ongoing oncology collaboration in China, the world's second largest pharmaceutical market.